Scarica l'app Stockscreener
1.41
7.63%
0.10
Pre-mercato:
1.42
0.01
+0.71%
Precedente Chiudi:
$1.31
Aprire:
$1.43
Volume 24 ore:
453.75K
Relative Volume:
3.23
Capitalizzazione di mercato:
$22.05M
Reddito:
-
Utile/perdita netta:
$-8.29M
Rapporto P/E:
-2.0143
EPS:
-0.7
Flusso di cassa netto:
$-6.47M
1 W Prestazione:
+6.82%
1M Prestazione:
+0.71%
6M Prestazione:
+14.63%
1 anno Prestazione:
-36.77%
Intervallo 1D:
$1.40
$1.54
Intervallo di 1 settimana:
$1.24
$1.54
Portata 52W:
$0.94
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Confronta NNVC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.41 | 20.65M | 0 | -8.29M | -6.47M | -0.70 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive financial news
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - The Derrick
NanoViricides: MPox ethics approval enables Phase 2 applicationPreview | NYSE-A:NNVC - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive Investors
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides to Present Innovative Antiviral Drug Research at D. Boral Capital Conference - citybuzz -
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC - The Globe and Mail
Geode Capital Management LLC Acquires 31,956 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Advances Broad-Spectrum Antiviral Drug for Measles Treatment - citybuzz -
NanoViricides advances measles drug development amid rising US cases | NYSE-A:NNVC - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
Measles is Likely to Become EndemicNanoViricides Is Testing a Drug to Combat It - The Derrick
New research warns measles could become endemic again in the US as vaccination rates fall - Proactive financial news
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market"Conclude Two Independent Research Reports on NanoViricides - ACCESS Newswire
Nanostructured Drug Market Projected for Significant Expansion by 2032 -Nanoviricides Inc, Ablynx NV, Pfizer - newstrail.com
Small cap wrap: Gunnison Copper, Ocean Power Technologies, NanoViricides... - Proactive financial news
NanoViricides evaluating antiviral drug NV-387 for measles treatment - Proactive financial news
Measles Outbreak Expands Begging for a Drug to Treat the InfectionNanoViricides Declares it is Ready to Fight the Outbreak - Lelezard
NanoViricides, Inc. Appoints Irach Taraporewala as the New CEO and Nominates to Serve as a Member of the Board of Directors - marketscreener.com
Nanostructured Drug Market Detailed In New Research Report 2025 | Nanoviricides Inc., Ablynx NV, Pfizer - newstrail.com
NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire
NanoViricides unaffected by US tariff turmoil, says CFO - Proactive financial news
NNVC stock touches 52-week low at $1.02 amid market challenges - Investing.com Canada
NanoViricides unimpacted by tariffs; sees boost by changes at government agencies - Proactive Investors
NNVC stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate - Proactive financial news
Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors
NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):